Company Information
Ask for more detail from the seller
Contact SupplierAt present, Rituximab is the most important mAb of clinical value in patients with Bcell lymphoid malignancies. RituxiRel is currently approved in two indications: Non- Hodgkin's Lymphoma (NHL), blood cancer and Rheumatoid Arthritis (RA).